Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2025-05-27 Capital/Financing Update
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Hyundai Bio regarding the acquisition of convertible bonds before maturity (early redemption). It details the bond series, acquisition amount, reason for acquisition (early redemption request by bondholders), and the method of disposal (cancellation). This falls under capital structure changes and financing updates, specifically related to debt instruments.
2025-05-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (pledges) of a major shareholder (CnPharm Co., Ltd.) in Hyundai Bioscience. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes in control.
2025-05-16 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Hyundai Bioscience Co., Ltd., covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements of a major shareholder (CnPharm) in Hyundai Bioscience. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-05-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (pledges) of a major shareholder (CnPharm) in Hyundai Bioscience. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-04-30 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CP-COV03의 2/3상 임상시험계획 승인)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a clinical trial plan (Phase 2/3) for a drug candidate. It details the clinical trial objectives, methodology, and regulatory approval status from the Vietnam Ministry of Health. Since it is a specific regulatory announcement regarding company operations and clinical progress that does not fit into financial reporting or other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-04-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.